The first generic twice-yearly HIV prevention injection cleared an FDA step.
Tentative approval is a regulatory milestone—not final U.S. approval or proof that broad access has already arrived.
Dr. Reddy's generic twice-yearly injectable lenacapavir received FDA tentative approval for HIV prevention, the first generic version to reach that milestone.
WHAT HAPPENED
The Clinton Health Access Initiative announced the milestone on November 2. Under a voluntary licence, the product is intended for 120 low- and lower-middle-income countries. CHAI says it is expected to cost $40 per person per year, with initial supply by the end of 2026 and wider availability during 2027—subject to country approvals, purchasing, financing and health-system delivery.
WHY THIS IS HOPESLOP
A prevention option given only twice a year could reduce the daily friction of pills and make sustained protection more practical. The good news is a real regulatory and manufacturing step, not a victory lap: affordability, procurement and country-level access now have to turn that step into doses people can actually receive.
ORIGINAL SOURCEClinton Health Access InitiativeRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.
MORE HOPESLOP
The first 1,000 native trees took root along the Guadalupe River.
The locally collected seedlings begin a five-year, 50,000-tree recovery plan.
Two Kauaʻi state parks reopened after two months of hurricane repairs.
Major lookouts and several trails are open again, though repairs and closures continue.
Virginia voters approved an equal-marriage amendment.
The result reverses a 2006 state constitutional ban; certification is still pending.